Simonneau G. Montani D. Celermajer D.S. et al.

Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Eur Respir J. 53https://doi.org/10.1183/13993003.01913-2018Gavilanes F. Fernandes C.J. Souza R.

Pulmonary arterial hypertension in schistosomiasis.

Curr Opin Pulm Med. 22: 408-414Gryseels B. Polman K. Clerinx J. et al.

Human schistosomiasis.

Lancet. 368: 1106-1118Colley D.G. Bustinduy A.L. Secor W.E. et al.

Human schistosomiasis.

Lancet. 383: 2253-2264Lapa M. Dias B. Jardim C. et al.

Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis.

Circulation. 119: 1518-1523Hatz C. Jenkins J.M. Ali Q.M. et al.

A review of the literature on the use of ultrasonography in schistosomiasis with special reference to its use in field studies. 2. Schistosoma mansoni.

Acta Trop. 51: 15-28Sibomana J.P. Campeche A. Carvalho-Filho R.J. et al.

Schistosomiasis Pulmonary Arterial Hypertension.

Front Immunol. 11: 608883Hoette S. Figueiredo C. Dias B. et al.

Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension.

BMC Pulm Med. 15: 118Mauad T. Pozzan G. Lancas T. et al.

Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension.

J Infect. 68: 90-98dos Santos Fernandes C.J. Jardim C.V. Hovnanian A. et al.

Survival in schistosomiasis-associated pulmonary arterial hypertension.

J Am Coll Cardiol. 56: 715-720Fernandes C. Dias B.A. Jardim C.V.P. et al.

The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension.

Chest Apr. 141: 923-928Fernandes C.J.C. Piloto B. Castro M. et al.

Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era.

Eur Respir J. 51https://doi.org/10.1183/13993003.00307-2018Fernandes C.J. Calderaro D. Assad A.P.L. et al.

Update on the Treatment of Pulmonary Arterial Hypertension.

Arq Bras Cardiol. 117 (): 750-764Baughman R.P. Field S. Costabel U. et al.

Sarcoidosis in America. Analysis Based on Health Care Use.

Ann Am Thorac Soc. 13: 1244-1252Belperio J.A. Shaikh F. Abtin F.G. et al.

Diagnosis and Treatment of Pulmonary Sarcoidosis: A Review.

JAMA. 327: 856-867Kirkil G. Lower E.E. Baughman R.P.

Predictors of Mortality in Pulmonary Sarcoidosis.

Chest. 153: 105-113Jeny F. Uzunhan Y. Lacroix M. et al.

Predictors of mortality in fibrosing pulmonary sarcoidosis. Respiratory medicine.

Aug. 169: 105997https://doi.org/10.1016/j.rmed.2020.105997Bourbonnais J.M. Samavati L.

Clinical predictors of pulmonary hypertension in sarcoidosis.

Eur Respir J Aug. 32: 296-302Shlobin O.A. Kouranos V. Barnett S.D. et al.

Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry.

Eur Respir J. 55https://doi.org/10.1183/13993003.01747-2019Shorr A.F. Helman D.L. Davies D.B. et al.

Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics.

Eur Respir J. 25: 783-788Huitema M.P. Bakker A.L.M. Mager J.J. et al.

Prevalence of pulmonary hypertension in pulmonary sarcoidosis: the first large European prospective study.

Eur Respir J. 54https://doi.org/10.1183/13993003.00897-2019Pabst S. Hammerstingl C. Grau N. et al.

Pulmonary arterial hypertension in patients with sarcoidosis: the Pulsar single center experience.

Adv Exp Med Biol. 755: 299-305Bandyopadhyay D. Humbert M.

An update on sarcoidosis-associated pulmonary hypertension.

Curr Opin Pulm Med. 26: 582-590Nunes H. Humbert M. Capron F. et al.

Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.

Thorax. 61: 68-74Baughman R.P. Shlobin O.A. Wells A.U. et al.

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Respir Med. 139: 72-78Ozyilmaz E. Akilli R. Berk I. et al.

The frequency of diastolic dysfunction in patients with sarcoidosis and it's relationship with HLA DRB1∗ alleles.

Sarcoidosis Vasculitis Diffuse Lung Dis. 36: 285-293Ungprasert P. Crowson C.S. Matteson E.L.

Association of Sarcoidosis With Increased Risk of VTE: A Population-Based Study, 1976 to 2013.

Chest. 151: 425-430Savale L. Huitema M. Shlobin O. et al.

WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.

Eur Respir Rev. : 31https://doi.org/10.1183/16000617.0165-2021Perlman D.M. Sudheendra M.T. Furuya Y. et al.

Clinical Presentation and Treatment of High-Risk Sarcoidosis.

Ann Am Thorac Soc. 18: 1935-1947Keir G.J. Walsh S.L. Gatzoulis M.A. et al.

Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.

Sarcoidosis Vasculitis Diffuse Lung Dis. 31: 82-90Boucly A. Cottin V. Nunes H. et al.

Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension.

Eur Respir J. 50https://doi.org/10.1183/13993003.00465-2017Baughman R.P. Shlobin O.A. Gupta R. et al.

Riociguat for Sarcoidosis-Associated Pulmonary Hypertension: Results of a 1-Year Double-Blind, Placebo-Controlled Trial.

Chest. 161: 448-457Waxman A. Restrepo-Jaramillo R. Thenappan T. et al.

Inhaled Treprostinil in Pulmonary Hypertension Due to Interstitial Lung Disease.

N Engl J Med. 384: 325-334Gunther S. Perros F. Rautou P.E. et al.

Understanding the Similarities and Differences between Hepatic and Pulmonary Veno-Occlusive Disease.

Am J Pathol. 189: 1159-1175Montani D. Achouh L. Dorfmuller P. et al.

Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology.

Medicine (Baltimore). 87: 220-233Montani D. Lau E.M. Descatha A. et al.

Occupational exposure to organic solvents: a risk factor for pulmonary veno-occlusive disease.

Eur Respir J. 46: 1721-1731Laveneziana P. Montani D. Dorfmuller P. et al.

Mechanisms of exertional dyspnoea in pulmonary veno-occlusive disease with EIF2AK4 mutations.

Eur Respir J. 44: 1069-1072Weatherald J. Dorfmuller P. Perros F. et al.

Pulmonary capillary haemangiomatosis: a distinct entity?.

Eur Respir Rev : official J Eur Respir Soc. : 29https://doi.org/10.1183/16000617.0168-2019Ogawa A. Sakao S. Tanabe N. et al.

Use of vasodilators for the treatment of pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis: A systematic review.

Respir Investig. 57: 183-190Montani D. Girerd B. Jais X. et al.

Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study.

Lancet Respir Med. 5: 125-134Emile J.F. Cohen-Aubart F. Collin M. et al.

Histiocytosis.

Lancet. 398: 157-170

Update on Pulmonary Langerhans Cell Histiocytosis.

Front Med (Lausanne). 7: 582581Heiden G.I. Sobral J.B. Freitas C.S.G. et al.

Mechanisms of Exercise Limitation and Prevalence of Pulmonary Hypertension in Pulmonary Langerhans Cell Histiocytosis.

Chest. 158: 2440-2448Dauriat G. Mal H. Thabut G. et al.

Lung transplantation for pulmonary langerhans' cell histiocytosis: a multicenter analysis.

Transplantation. 81: 746-750Fartoukh M. Humbert M. Capron F. et al.

Severe pulmonary hypertension in histiocytosis X.

Am J Respir Crit Care Med. 161: 216-223Le Pavec J. Lorillon G. Jais X. et al.

Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies.

Chest. 142: 1150-1157Kavanagh P.L. Fasipe T.A. Wun T.

Sickle Cell Disease: A Review.

JAMA. 328: 57-68Piel F.B. Hay S.I. Gupta S. et al.

Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.

Plos Med. 10: e1001484

Chronic Pulmonary Complications of Sickle Cell Disease.

Chest. 149: 1313-1324Alves J.L. Oleas F.G. Souza R.

Pulmonary Hypertension: Definition, Classification, and Diagnosis.

Semin Respir Crit Care Med. 38: 561-570Parent F. Bachir D. Inamo J. et al.

A hemodynamic study of pulmonary hypertension in sickle cell disease.

N Engl J Med. 365: 44-53Fonseca G.H. Souza R. Salemi V.M. et al.

Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease.

Eur Respir J. 39: 112-118Mehari A. Gladwin M.T. Tian X. et al.

Mortality in adults with sickle cell disease and pulmonary hypertension.

JAMA. 307: 1254-1256Gladwin M.T. Sachdev V. Jison M.L. et al.

Pulmonary hypertension as a risk factor for death in patients with sickle cell disease.

N Engl J Med. 350: 886-895Carstens G.R. Paulino B.B.A. Katayama E.H. et al.

Clinical relevance of pulmonary vasculature involvement in sickle cell disease.

Br J Haematol. 185: 317-326Ribeiro de Campos P.T. Lopes A.A. Issa V.S. et al.

Morphologic and immunohistochemical features of pulmonary vasculopathy in end-stage left ventricular systolic failure.

J Heart Lung Transplant. 37: 422-425Wood K.C. Gladwin M.T. Straub A.C.

Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.

Heart. 106: 562-568Klings E.S. Machado R.F. Barst R.J. et al.

An official American Thoracic Society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.

Am J Respir Crit Care Med. 189: 727-740Machado R.F. Barst R.J. Yovetich N.A. et al.

Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity.

Blood. 118: 855-864Cramer-Bour C. Ruhl A.P. Nouraie S.M. et al.

Long-term tolerability of phosphodiesterase-5 inhibitors in pulmonary hypertension of sickle cell disease.

Eur J Haematol. 107: 54-62Barst R.J. Mubarak K.K. Machado R.F. et al.

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Br J Haematol. 149: 426-435